셀투인은 연구개발 결과를 특허등록, 학술지 게재 및 국제학회 기술 발표를 통해
기술의 우수성과 신뢰성을 입증하고 있습니다.
지적재산권 확보
Cell2in은 글로벌 바이오 시장에서 고유 기술을 활용한 적극적 사업 전개를 위해 국내는 물론 신약개발 주요국가의 고품질 세포치료제 생산기술의 특허를 확보하고 있습니다.
물질 및 용도
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| 세포의 티올수준을 측정하기 위한 실시간 이미징 센서 |
Korea | 10-1862581 | 2018. 05. 24 |
| United States | 10.215.757B2 | 2019. 02. 26 | |
| Korea | 10-1983803 | 2019. 05. 23 | |
| United States | 10.620.215 | 2020. 04. 14 | |
| 세포의 소기관 내 글루타치온 측정용 실시간 형광 이미징 센서 및 이의 제조방법 |
Korea | 10-2133794 | 2020. 07. 08 |
| Canada (application) | 3.072.434 | 2020. 02. 07 | |
| Australia (application) | 2018320601 | 2020. 02. 19 | |
| United States (application) | 16/640717 | 2020. 02. 20 | |
| Europe (application) | 18848372.1 | 2020. 02. 21 | |
| China (application) | 201880054675.0 | 2020. 02. 21 | |
| India (application) | 202017007994 | 2020. 02. 25 | |
| Japan (application) | 2020-511502 | 2020. 02. 19 | |
| 소포체 내 글루타치온 측정용 실시간 형광 이미지 센서 및 이를 이용하는 방법 |
Korea | 10-2019-0178260 | 2019. 12. 30 |
Gene Biomarker
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| FreSHtracer 기반 분리된 세포의 유전자 프로파일의 응용 |
PCT | PCT/KR 2018/008239 | 2018. 07. 20 |
Stem Cell Therapy
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| 혈소판 감소증 치료용 조성물 |
Korea | 10-2021-0063975 | 2021. 05. 18 |
| 고품질의 줄기세포 선별용 마커 및 이를 이용한 고품질 줄기세포 선별 방법 |
Korea | 10-2020-0180455 | 2020. 12. 22 |
Cell Quality Control
| Name of Technology | Country of Application | Application and Registration No. | Applied and Registered Date |
|---|---|---|---|
| 실시간 글루타치온 측정을 통한 치료용 세포의 품질 향상 방법 |
Korea | 10-2119714 | 2020. 06. 01 |
| Europe (application) | 18883520.1 | 2020. 05. 27 | |
| China (application) | 201880077266.2 | 2020. 05. 28 | |
| Japan (application) | 2020-546264 | 2020. 05. 27 | |
| United States (application) | 16/767985 | 2020. 05. 28 | |
| 실시간 글루타치온 측정을 통한 치료용 세포의 품질 측정 방법 |
Korea | 10-2145929 | 2020. 08. 12 |
| United States (application) | 16/768014 | 2020. 05. 28 | |
| Europe (application) | 18884812.1 | 2020. 05. 27 | |
| China (application) | 201880077236.1 | 2020. 05. 28 | |
| Japan (application) | 2020-546265 | 2020. 05. 27 |
기술 발표 및 게재
셀투인은 국내외 학회와 학술지를 통해 연구 성과를 지속적으로 발표해오고 있습니다.
Development Technology and Pluripotent Stem Cells : K. Kim et al., Improved Isolation and Culture of Urine-Derived Stem Cells (USCs) and Enhanced Production of Immune Cells from the USC-Derived Induced Pluripotent Stem Cells, J. Clin. Med. (2020), 9, 827
The availability of autologous adult stem cells is one of the essential prerequisites for
human stem cell therapy. Urine-derived stem cells (USCs) are considered as desirable cell sources for
cell therapy because donor-specific USCs are easily and non-invasively obtained from urine. Efficient
isolation, expansion, and differentiation methods of USCs are necessary to increase their availability.
Here, we developed a method for efficient isolation and expansion of USCs using Matrigel, and the
rho-associated protein kinase (ROCK) inhibitor, Y-27632. The prepared USCs showed significantly
enhanced migration, colony forming capacity, and differentiation into osteogenic or chondrogenic
lineage. The USCs were successfully reprogramed into induced pluripotent stem cells (USC-iPSCs)
and further differentiated into kidney organoid and hematopoietic progenitor cells (HPCs). Using
flavonoid molecules, the isolation efficiency of USCs and the production of HPCs from the USC-iPSCs
was increased. Taken together, we present an improved isolation method of USCs utilizing Matrigel,
a ROCK inhibitor and flavonoids, and enhanced differentiation of USC-iPSC to HPC by flavonoids.
These novel findings could significantly enhance the use of USCs and USC-iPSCs for stem cell research
and further application in regenerative stem cell-based therapies.
human stem cell therapy. Urine-derived stem cells (USCs) are considered as desirable cell sources for
cell therapy because donor-specific USCs are easily and non-invasively obtained from urine. Efficient
isolation, expansion, and differentiation methods of USCs are necessary to increase their availability.
Here, we developed a method for efficient isolation and expansion of USCs using Matrigel, and the
rho-associated protein kinase (ROCK) inhibitor, Y-27632. The prepared USCs showed significantly
enhanced migration, colony forming capacity, and differentiation into osteogenic or chondrogenic
lineage. The USCs were successfully reprogramed into induced pluripotent stem cells (USC-iPSCs)
and further differentiated into kidney organoid and hematopoietic progenitor cells (HPCs). Using
flavonoid molecules, the isolation efficiency of USCs and the production of HPCs from the USC-iPSCs
was increased. Taken together, we present an improved isolation method of USCs utilizing Matrigel,
a ROCK inhibitor and flavonoids, and enhanced differentiation of USC-iPSC to HPC by flavonoids.
These novel findings could significantly enhance the use of USCs and USC-iPSCs for stem cell research
and further application in regenerative stem cell-based therapies.
학술지 게재
| 『Stem Cell Report』 |  |
| 『The Journal of Clinical Investigation』 |  |
| 『Science Advances』 |  |
기술 발표
| 국제줄기세포학회 기술 발표 |  |